Probably non-CYP metabolism. No data pointing to any interaction with the metabolism of CYP-metabolised drugs.

Selective inhibitor of intestinal cholesterol absorbtion. Mainly metabolized in the liver and intestinal wall via glucuroidation (phase II reaction) and eliminated via bile.

Uneventful use reported in 8 patients with acute porphyria.